AZALEA-TIMI 71 is a phase 2b, multicenter, randomized, active-controlled study to evaluate the safety and tolerability of two blinded doses of the novel factor XI inhibitor abelacimab compared with open-label rivaroxaban in patients with atrial fibrillation.
MAIN RESULTS:
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
N Engl J Med. 2025 Jan 23;392(4):361-371.
MAIN RESULTS PRESENTATION
OTHER PRESENTATIONS
Long-acting Factor XI Inhibition and Periprocedural Bleeding (Patel, ESC 2024)
Bleeding with the FXI Inhibitor Abelacimab compared with Rivaroxaban in Patients on Antiplatelet therapy-A Prespecified Analysis of the AZALEA-TIMI 71 Trial (Al Said, AHA 2024)
Bleeding with the FXI Inhibitor Abelacimab Compared with Rivaroxaban in Older Individuals-Analysis of the AZALEA-TIMI 71 Trial (Al Said, ACC 2025)
Factor XI Inhibition with Abelacimab in Atrial Fibrillation Across the Spectrum of Bleeding Risk (Patel, ACC 2025)
Prior anticoagulation experience, bleeding risk, and safety of factor XI inhibition in atrial fibrillation-an analysis of AZALEA-TIMI 71 (Patel, ESC 2025)
Renal function and factor XI inhibition in atrial fibrillation-a pre-specified analysis of AZALEA-TIMI 71 (Patel, ESC 2025)
PUBLICATIONS
AZALEA on ClinicalTrials.gov
CONTACT US about AZALEA